NR3C2 and hydrops fetalis: Additional changes to HF therapy (either a change in existing medication or a new treatment started) included an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in 72 (17.7%) patients, sacubitril/valsartan in 29 (7.1%), a β-blocker in 47 (11.5%), a mineralocorticoid receptor in 58 (14.3%), a vasodilator in 11 (2.7%), and another HF medication in 49 (12.0%).